Abstract

Pulmonary epithelioid hemangioendothelioma (PEH) is a rare vascular tumor of borderline or low-grade malignancy, Vascular endothelial growth factor (VEGF) and the VEGF receptor were found on PEH tumor cells, suggesting that target therapies that block VEGFR have a logical base in this rare malignancy. We report a 25 years old woman with a pulmonary hemangioendothelioma, treated with pazopanib, the only anti angiogenic registered agent for sarcoma, with clinical improvement of symptoms and durable stabilization for more than two years of lung tumor.

Keywords: morocco, Hemangioendothelioma

Downloads

Download data is not yet available.

Most read articles by the same author(s)

 How to Cite
Ahalli, I., Oualla, K., Hejjane, L., Boujarnija, R., Messoudi, K., Mai, A., … Mellas, N. (2020). Pazopanib in Pulmonary Epithelioid Hemangioendothelioma: Report of a Case. International Journal of Innovative Research in Medical Science, 5(02), 84 to 87. https://doi.org/10.23958/ijirms/vol05-i02/828

Copyrights & License